Released May 14, 2021, before the open
10-Q filed May 17, 2021, 47 days after period end · 0001437749-21-012546
Q1 2021 · 10-Q
Revenue$1.89M$1.89M +261.5% vs Q1 2020+77.5% vs Q4 2020
Net Income-$851.43K-$851.43K N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.11-$0.11 N/M vs Q1 2020no prior Q4 2020 on file
Gross Profit$1,122,003+181.8%
Operating Income-$836,046N/M
Operating Cash Flow-$3,198,559N/M
Free Cash Flowderived-$3,211,866—
Margins · derived
Gross margin59.4%−16.8 pt vs Q1 2020
Operating margin-44.3%+348.1 pt vs Q1 2020
Net margin-45.1%+600.0 pt vs Q1 2020
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $1.89M | $522.49K | $551.62K | $841.46K |
| Net Income | -$851.43K | -$3.37M | -$1.80M | -$2.19M |
| EPS Diluted | -$0.11 | -$1.84 | -$0.13 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio Key International Inc · CIK 1019034 · Engraved from SEC EDGAR